DHFR and cancer: Inhibition of folate metabolism is the basis for several widely used cancer drugs, including methotrexate [1-3], which exerts its toxicity by inhibiting dihydrofolate reductase (DHFR) thereby disrupting purine and thymidylate biosynthesis, inhibiting DNA replication and promoting cell death.